Table 1. Patient’s characteristics at ART initiation.
IeDEA West Africa collaboration, 2002–2015 (N = 9,426).
| Characteristics | All (N = 9,426) | |
|---|---|---|
| HIV clinic, Country; n (%) | ||
| CePReF, Cote d’Ivoire | 3,529 | (37.4) |
| CNTS, Cote d’Ivoire | 1,502 | (15.9) |
| MTCTP, Cote d’Ivoire | 462 | (4.9) |
| BOBO, Burkina Faso | 1,956 | (20.8) |
| CHUYO, Burkina Faso | 279 | (3.0) |
| CNHU, Benin | 816 | (8.7) |
| Gabriel Toure, Mali | 559 | (5.9) |
| SMITD, Senegal | 323 | (3.4) |
| Calendar year for ART initiation; median [IQR] | 2009 | [2006–2011] |
| Gender; n (%) | ||
| Female | 6,598 | (70.0) |
| Male | 2,828 | (30.0) |
| Age (years); n (%) | ||
| <35 | 4,024 | (42.7) |
| ≥35 | 5,402 | (57.3) |
| Clinical stage (CDC 3 or WHO 4); n (%) | ||
| No | 5,930 | (62.9) |
| Yes | 1,557 | (16.5) |
| Missing | 1,939 | (20.6) |
| CD4 count (cells/mm3); n (%) | ||
| <350 | 7,314 | (77.6) |
| ≥350 | 1,122 | (11.9) |
| Missing | 990 | (10.5) |
| Neutrophils count (cells/mm3); n (%) | ||
| ≥1,300 | 7,944 | (84.3) |
| 1,000–1,300 | 1,034 | (11.0) |
| 750–1,000 | 448 | (4.8) |
| Hemoglobin level (g/dL); n (%) | ||
| ≥10 | 5,974 | (63.4) |
| 7.5–10 | 2,307 | (24.5) |
| <7.5 | 629 | (6.7) |
| Missing | 516 | (5.5) |
| ART regimen containing ZDV; n (%) | ||
| No | 4,345 | (46.1) |
| Yes | 5,081 | (53.9) |
| First-line ART regimen; n (%) | ||
| ZDV/3TC/EFV | 2,195 | (23.3) |
| ZDV/3TC/NVP | 2,307 | (24.5) |
| D4T/3TC/EFV | 819 | (8.7) |
| D4T/3TC/NVP | 1,426 | (15.1) |
| TDF-based regimens | 1,590 | (16.9) |
| Other regimens | 1,089 | (11.6) |
IQR, interquartile range; CI, confidence interval; ART, antiretroviral therapy; CDC, US Centers for Disease Control; WHO, World Health Organization; ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; TDF, tenofovir; FTC, emtricitabine.